MyC, a French occupational health management platform for industrial and multi-site groups, announced on 3 February 2026 a €10 million funding round led by Hi inov, with participation from IXO and existing investors Elaia and OSS Ventures. The funding will accelerate product development around AI and international expansion, with the company already serving nearly 400 sites in more than 60 countries.
A round led by Hi inov, a European B2B fund
According to J'aime les startups, the round is led by Hi inov, a European asset manager specializing in B2B SaaS, alongside IXO Private Equity, Elaia Partners (an investor since the €2 million seed round covered by FrenchWeb) and OSS Ventures.
MyC was founded in 2020 in Paris by Dr Laurent Bonnardot, an ENT specialist and emergency physician who has practiced in remote environments, and Benjamin Crevant, an entrepreneur with a background in industry. The company employs around 30 people and reports more than 1,000 monthly active users across its clients, for a total of over 500,000 beneficiaries (covered employees).
The segment: multisite occupational health on an international scale
MyC's target market is large multisite industrial groups exposed to significant occupational risks: energy, mining, construction, transport, defense, oil & gas, and food processing. For these companies, occupational health is a regulatory issue (mandatory medical examinations, exposure monitoring), an HR issue (retention, engagement) and an operational issue (reducing work stoppages, ISO 45001 compliance).
The complexity lies in the diversity of national regulatory frameworks. A multinational operating fifty sites across twenty countries juggles just as many labor codes, health agencies and medical record formats. MyC's promise is to unify management through a single cloud platform, while guaranteeing local compliance (GDPR in Europe, HIPAA in the United States, specific standards in Africa and the Middle East).
Generative AI as a product accelerator
The AI direction announced by MyC is part of a structural shift in B2B health SaaS. Likely use cases: automatic extraction of information from medical reports (unstructured document analysis), support in drafting fitness-for-work certificates, detection of weak epidemiological signals across employee populations, and generation of HSE reports for regulators. These features follow the trail blazed by US medtech vendors such as Veeva or IQVIA, which dominate clinical data solutions for pharma.
The occupational health platform market: a consolidating landscape
According to a DSIH study also covered by FrenchWeb, French e-health start-ups raised €1.16 billion in 2022. The occupational health segment proper remains smaller, dominated in France by AESIO Mutuelle (a long-standing mutual player), Padoa (an occupational health start-up focused on SMEs and mid-caps) and, more recently, Lilo. Internationally, the UK's LiVi, Germany's Fernarzt and the US's Lyra Health address comparable territories with distinct angles.
MyC's key differentiator is its vertical focus on large industrial accounts with multi-country compliance requirements, where competitors mostly target SMEs and mid-cap companies or individuals. This niche means a long sales cycle (12 to 18 months) but large annual contracts (typically 200,000 to 1 million euros per group depending on scope), with a naturally high retention rate once deployment is complete.
Execution challenges
- Product localization: adapting the platform to 60+ regulatory frameworks without degrading time-to-deploy remains a structural challenge.
- Security and health data hosting: HDS certification in France and equivalent country-specific certifications (ISO 27001, SOC 2 type II) are non-negotiable prerequisites for large accounts.
- Complex sales: addressing HR, HSE management, IT, and the occupational physician at the same time requires a sophisticated sales team able to translate the value for each buyer persona.
What's the trajectory after this raise?
For MyC, the next 12 to 24 months must validate three milestones:
- Industrializing the AI layer into daily workflows (not as a gimmick feature).
- Geographic expansion beyond historical strongholds (Europe, French-speaking Africa, the Middle East) into North America and Asia-Pacific.
- Growing from roughly 30 to 60-80 employees without degrading service quality or the NPS of existing clients.
For the marketing and operations leadership of B2B SaaS companies in international scale-up mode, these challenges around industrialization, operational AI, and sales structuring are recurring workstreams. Growth marketing agencies and applied AI teams can help structure the key account acquisition layer and automate support operations.
FAQ
What is the amount and type of MyC's funding round?
On February 3, 2026, MyC announced a €10 million raise, described as a Series A by some sources and a growth round by others, led by Hi inov, with IXO, Elaia Partners, and OSS Ventures.
Who are MyC's founders?
MyC was founded in 2020 in Paris by Dr Laurent Bonnardot, an ENT physician and emergency doctor, and Benjamin Crevant, an entrepreneur with a background in industry. The company combines medical expertise with an understanding of industrial operational constraints.
What is MyC's commercial traction?
The company serves nearly 400 sites in more than 60 countries, with over 1,000 monthly active users and 500,000 beneficiaries (covered employees). It targets large multisite industrial groups with international compliance requirements.
What will this €10M raise be used for?
The funding will accelerate product development around artificial intelligence (document extraction, medical decision support, HSE reporting) and support international commercial expansion, particularly into North America and Asia-Pacific.
Who are MyC's direct competitors in France?
In the French occupational health segment, the main identified competitors are Padoa (focused on SMEs and mid-caps), Lilo, and established mutualist players like AESIO. Internationally, vendors such as LiVi (UK), Fernarzt (Germany), and Lyra Health (US) address similar scopes with different angles.